MICHAEL HORD: Open Payments
NPI 1205864626 · BROWNFIELD, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,817 in 103 payments from 23 companies in 2025. Trend: 2023 $1,839 · 2024 $1,800 · 2025 $1,817
Food & beverage: $1,817
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $190 |
| GlaxoSmithKline, LLC. | 17 | $185 |
| Novo Nordisk Inc | 10 | $164 |
| Axsome Therapeutics, Inc. | 9 | $162 |
| Bayer Healthcare Pharmaceuticals Inc. | 8 | $153 |
| Lilly USA, LLC | 7 | $118 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $117 |
| Sumitomo Pharma America, Inc. | 5 | $106 |
| Aimmune Therapeutics, Inc. | 4 | $97 |
| Otsuka America Pharmaceutical, Inc. | 3 | $75 |
Products named: Auvelity, Kerendia, TRELEGY ELLIPTA, MOUNJARO, XIFAXAN, FARXIGA, GEMTESA, REXULTI.
Industry payments across TX — which companies pay providers there.
